Free tool
Drug Trial Radar: Oncology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
1,443
Recruiting, industry sponsors, Oncology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting1,443
- Completed4,611
1,443 trials
Showing 1 to 25, recently updated first.
PfizerPfizer (PFE)
NCT07476287 · 40 participants (planned) · Start Jul 2, 2026 · Primary completion Mar 24, 2028
Drug: PF-08634404; Chemotherapy · For: Small Cell Lung Cancer; Small Cell Lung Cancer ( SCLC ); Transformed Small Cell Lung Cancer and 3 more
Sites: Duarte, California; Encinitas, California; Irvine, California · 75 sites in all
PfizerPfizer (PFE)
NCT07227298 · 162 participants (planned) · Start Jan 30, 2026 · Primary completion Mar 8, 2029
Drug: PF-08634404; Sigvotatug Vedotin and 1 more · For: Advanced/Metastatic Non-Small Cell Lung Cancer; Carcinoma, Non-Small Cell Lung; Non-Small Cell Lung Cancer
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 108 sites in all
Aeovian Pharmaceuticals, Inc.Industry
NCT07680322 · 42 participants (planned) · Start Oct 5, 2026 · Primary completion Sep 1, 2027
Drug: AV078; Placebo · For: Tuberous Sclerosis Complex; Epilepsy
Sites: London, Canada
PfizerPfizer (PFE)
NCT07227012 · 138 participants (planned) · Start Dec 1, 2025 · Primary completion Oct 18, 2027
Drug: PF-08634404; Ipilimumab · For: Carcinoma, Hepatocellular; Hepatocellular Cancer; Hepatocellular Carcinoma and 4 more
Sites: Phoenix, Arizona; Irvine, California; Los Angeles, California · 81 sites in all
Molecular Partners AGIndustry
NCT07278479 · 138 participants (planned) · Start May 18, 2026 · Primary completion Sep 2028
Drug: [212Pb]Pb-MP0712 · For: Large Cell Neuroendocrine Carcinoma; Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) and 4 more
Sites: Miami, Florida; Tampa, Florida; Atlanta, Georgia · 9 sites in all
Adcendo ApSIndustry
NCT06797999 · 270 participants (planned) · Start Jun 5, 2025 · Primary completion Feb 27, 2029
Drug: Antibody-drug conjugate (ADC) · For: Metastatic Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma
Sites: Aurora, Colorado; Miami, Florida; New York, New York · 9 sites in all
PfizerPfizer (PFE)
NCT07489066 · 120 participants (planned) · Start Jun 30, 2026 · Primary completion Jul 29, 2028
Drug: PF-08634404; Chemotherapy Regimen 1 and 1 more · For: Carcinoma; Non-Small-Cell Lung; Lung Cancer (NSCLC) and 6 more
Sites: Huntsville, Alabama; Stanford, California; Athens, Georgia · 66 sites in all
- A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06833073 · 308 participants (planned) · Start Mar 11, 2025 · Primary completion Sep 3, 2031
Drug: Intismeran autogene; BCG · For: Urinary Bladder Neoplasms; Non-Muscle Invasive Bladder Neoplasms; Carcinoma in Situ
Sites: Bakersfield, California; Los Alamitos, California; Los Angeles, California · 89 sites in all
PfizerPfizer (PFE)
NCT07421700 · 132 participants (planned) · Start Mar 11, 2026 · Primary completion Dec 28, 2027
Drug: PF-08634404; Enfortumab Vedotin · For: Urothelial Cancer; Advanced/Metastatic Urothelial Cancer; Urothelial Carcinoma
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 198 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT07100106 · 285 participants (planned) · Start Oct 7, 2025 · Primary completion Aug 31, 2028
Drug: GDC-4198; Giredestrant and 1 more · For: Breast Cancer
Sites: Huntsville, Alabama; Tucson, Arizona; Duarte, California · 77 sites in all
- Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07392892 · 840 participants (planned) · Start May 14, 2026 · Primary completion Jul 22, 2031
Drug: PF-08634404; Chemotherapy and 1 more · For: Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma; Metastatic Gastric Cancer; Gastroesophageal Junction Cancer and 1 more
Sites: Anaheim, California; Atascadero, California; Burbank, California · 124 sites in all
- Vortosiran for VTE PreventionPivotal-lookingRecruiting
Ribocure Pharmaceuticals ABIndustry
NCT07850453 · 150 participants (planned) · Start Nov 4, 2026 · Primary completion Jul 2027
Drug: Vortosiran; Placebo · For: Venous Thromboembolism (VTE); Cancer; Pulmonary Embolism (Diagnosis)
Sites: Pazardzhik, Bulgaria; Rousse, Bulgaria; Sofia, Bulgaria · 30 sites in all
Voronoi, IncIndustry
NCT07699328 · 315 participants (planned) · Start Mar 26, 2024 · Primary completion Jan 1, 2029
Drug: VRN110755 · For: EGFR-Mutant Non-Small Cell Lung Cancer
Sites: Bedford Park, Australia; Clayton, Australia; Toronto, Canada · 29 sites in all
Orca Biosystems, Inc.Industry
NCT07216443 · 130 participants (planned) · Start Dec 9, 2025 · Primary completion Nov 2028
Drug: Orca-T · For: Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Mixed Phenotype Acute Leukemia
Sites: Duarte, California; Los Angeles, California; Denver, Colorado · 9 sites in all
AmgenAmgen (AMGN)
NCT07172919 · 14 participants (planned) · Start Jan 2, 2026 · Primary completion Jul 1, 2028
Drug: Sotorasib; Panitumumab · For: Advanced Solid Tumors
Sites: Fort Myers, Florida; Houston, Texas; Randwick, Australia · 13 sites in all
Wayshine Biopharm, Inc.Industry
NCT06868485 · 40 participants (planned) · Start Aug 18, 2025 · Primary completion Sep 30, 2027
Drug: WSD0922-FU Tablets, Dose level A; WSD0922-FU Tablets, Dose level B · For: Non Small Cell Lung Cancer
Sites: Weston, Florida; Manahawkin, New Jersey; Teaneck, New Jersey · 16 sites in all
- Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07227415 · 224 participants (planned) · Start Feb 10, 2026 · Primary completion Nov 2, 2027
Drug: PF-08634404; Ipilimumab and 2 more · For: Carcinoma, Renal Cell; Advanced Renal Cell Carcinoma; Renal Cancer and 10 more
Sites: Phoenix, Arizona; Scottsdale, Arizona; Fayetteville, Arkansas · 186 sites in all
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung CancerPivotal-lookingRecruiting
Verastem, Inc.Industry
NCT07659782 · 105 participants (planned) · Start Jul 22, 2026 · Primary completion Jun 2027
Drug: VS-7375 · For: Non-Small Cell Lung Cancer
Sites: Scottsdale, Arizona; Los Angeles, California; Aurora, Colorado · 27 sites in all
AbbVieAbbVie (ABBV)
NCT07744126 · 150 participants (planned) · Start Sep 1, 2026 · Primary completion Oct 2029
Drug: Telisotuzumab Adizutecan; Pembrolizumab and 3 more · For: Head and Neck Squamous Cell Carcinoma
Sites: Duarte, California; Newnan, Georgia; Kobe, Japan · 9 sites in all
Tethra Biosciences Inc.Industry
NCT05358379 · 330 participants (planned) · Start Apr 14, 2022 · Primary completion Nov 2028
Drug: THT140 · For: Solid Tumor, Adult Lymphoma
Sites: New York, New York; Houston, Texas; Seattle, Washington · 5 sites in all
- Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)Recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
NCT07499362 · 20 participants (planned) · Start Mar 26, 2026 · Primary completion Aug 22, 2028
Drug: Pimicotinib · For: Tenosynovial Giant Cell Tumor
Sites: Chūōku, Japan; Fukuoka, Japan; Kanazawa, Japan · 7 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06926868 · 600 participants (planned) · Start Sep 11, 2025 · Primary completion Mar 13, 2028
Drug: Iza-bren; Nab-paclitaxel and 4 more · For: Breast Neoplasms
Sites: Hot Springs, Arkansas; Cerritos, California; Long Beach, California · 296 sites in all
Wuhan KadGeno Biotechnology Co., LtdIndustry
NCT07948083 · 304 participants (planned) · Start Jan 6, 2026 · Primary completion Nov 30, 2027
Drug: KDTV001 · For: HPV (Human Papillomavirus)-Associated; HPV 16/18; HPV 52 and 1 more
Sites: Wuhan, China · 2 sites in all
Stemline Therapeutics, Inc.Industry
NCT05386108 · 73 participants (planned) · Start Aug 31, 2022 · Primary completion Aug 2027
Drug: Elacestrant; Abemaciclib · For: Breast Neoplasms; Brain Neoplasms; Neoplasms by Site and 5 more
Sites: Fullerton, California; Los Angeles, California; Urbana, Illinois · 86 sites in all
- A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination TreatmentsPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT05714839 · 123 participants (planned) · Start Jun 14, 2023 · Primary completion Aug 3, 2028
Drug: Belantamab; Belantamab mafodotin and 2 more · For: Multiple Myeloma
Sites: Bullhead City, Arizona; Los Angeles, California; Pembroke Pines, Florida · 59 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.